|
|
|
European Biopharmaceutical Review
|
|
THE IMPROPER USE OF INFORMATION
Companies are awash with information, yet short on the tools, methods and talent for using it. Information about all facets of business is gathered but not sufficiently analysed, reported but not understood, and therefore not acted upon.
There are exceptions in areas such as customer information or production processes, but the R&D development process in the life sciences industry clearly lacks analytical tools that support business decisions in an environment that has to deal with budget constraints and a high chance of failure.
This has resulted in the now well-known statement that ‘it takes $1 billion to develop and commercialise a new drug’. Obviously this amount is inclusive of all research projects that have been aborted at some point in their development life, but the consequences of such a statement are great:
- It gives the impression that only very big companies with a lot of financial clout have the resources to develop new drugs
- It reinforces the already strong attitude towards creating increasingly bigger pharmaceutical companies that are, contrary to the a priori expectation, not necessarily more productive in the research environment
- Smaller biotech companies find it more difficult to attract money since the process of developing new drugs is deemed too risky
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Professor Roel Bellens is cofounder of the Financial Management department at the European University College, Brussels, and visiting professor at the universities of Louvain (Belgium), Groningen (The Netherlands), Sofia (Bulgaria), Saint Petersburg (Russia) and Stalowa Wola (Poland). From 1978 to 1986, Roel held senior positions at Johnson & Johnson in Japan and the UK. He is currently Managing Director of Strategus, an independent research and valuation consultancy. As a specialist in risk and value management, Roel has published more than 100 articles and case studies, as well as three books on value management, based on the integration of financial management, marketing and strategy, and he has advised many multinational companies. |
|
|
|
|
|
 |
Industry Events |
 |
5th Annual BioPharma Asia Convention 2012
19-22 March 2012, Marina Bay Sands, Singapore
BioPharma Asia Convention is the only event that brings together senior level executives from global and regional pharma companies, biotechs, CMOs, CROs, academic institutions, investors and all other industrial stakeholders to assess the latest industrial trends, partnership models and solutions in Asia.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
